Jinglin J Li

This inventor holds 17 USPTO granted patents and 1 published patent application. Top assignees: G.d. Searle & Company, Pharmacia Corporation. Active years: 1994-2008.

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 76.5

Average Co-Inventor Count = 4.6

ph-index = 7

Forward Citations = 418(Granted Patents)

Location History:

St. Louis, MO (US) (1996 - 1997)
Chesterfield, MO (US) (1994 - 2004)
Hopewell, NJ (US) (2002 - 2008)

Company Filing History:

14 out of 1,323

G.d. Searle & Company

patents

3 out of 220

Pharmacia Corporation

patents

Years Active: 1994-2008

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7420061 - Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors (2008-09-02),

2. 6815460 - Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors (2004-11-09),

3. 6784201 - Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake (2004-08-31),

4. 6436967 - Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors (2002-08-20),

5. 6387924 - Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake (2002-05-14),

6. 6262277 - Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake (2001-07-17),

7. 6107494 - Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal (2000-08-22),

8. 5994391 - Benzothiepines having activity as inhibitors of ileal bile acid (1999-11-30),

9. 5932598 - Prodrugs of benzenesulfonamide-containing COX-2 inhibitors (1999-08-03),

10. 5739166 - Substituted terphenyl compounds for the treatment of inflammation (1998-04-14),

11. 5736579 - Substituted spiro compounds for the treatment of inflammation (1998-04-07),

12. 5677296 - Carbamic acid derivatives of substituted dibenzoxazepine compounds, (1997-10-14),

13. 5663180 - Substituted cyclopentenes for the treatment of inflammation (1997-09-02),

14. 5488046 - Carbamic acid derivatives of substituted dibenzoxazepine compounds, (1996-01-30),

15. 5420287 - 1,2 diarylcyclopentenyl compounds for the treatment of inflammation (1995-05-30),

Title: The Innovative Contributions of Jinglin J Li

Introduction

Jinglin J Li is a prominent inventor based in Chesterfield, MO (US), known for her significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 17 patents, she has made strides in developing prodrugs that target inflammation and related disorders. Her work has had a substantial impact on the medical community and continues to influence research and development in this area.

Latest Patents

Among her latest patents, Jinglin J Li has developed processes for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors. These prodrugs are particularly useful in treating inflammation and inflammation-related disorders. The innovative methods she has described not only enhance the efficacy of COX-2 inhibitors but also provide new avenues for therapeutic applications.

Career Highlights

Throughout her career, Jinglin J Li has worked with notable companies such as G.D. Searle & Company and Pharmacia Corporation. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in the pharmaceutical industry. Her dedication to innovation is evident in her extensive patent portfolio.

Collaborations

Jinglin J Li has collaborated with esteemed colleagues, including David B Reitz and Len F Lee. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Jinglin J Li's contributions to the field of pharmaceuticals through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in treating inflammation and related disorders.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]